Synergy Between Beta-Lactams and Lipo-, Glyco-, and Lipoglycopeptides, Is Independent of the Seesaw Effect in Methicillin-Resistant .

Rutan Zhang, Ismael A Barreras Beltran, Nathaniel K Ashford, Kelsi Penewit, Adam Waalkes, Elizabeth A Holmes, Kelly M Hines, Stephen J Salipante, Libin Xu, Brian J Werth
Author Information
  1. Rutan Zhang: Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA, United States.
  2. Ismael A Barreras Beltran: Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, United States.
  3. Nathaniel K Ashford: Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, United States.
  4. Kelsi Penewit: Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, WA, United States.
  5. Adam Waalkes: Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, WA, United States.
  6. Elizabeth A Holmes: Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, WA, United States.
  7. Kelly M Hines: Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA, United States.
  8. Stephen J Salipante: Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, WA, United States.
  9. Libin Xu: Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA, United States.
  10. Brian J Werth: Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, United States.

Abstract

Methicillin-resistant (MRSA) are resistant to beta-lactams, but synergistic activity between beta-lactams and glycopeptides/lipopeptides is common. Many have attributed this synergy to the beta-lactam-glycopeptide seesaw effect; however, this association has not been rigorously tested. The objective of this study was to determine whether the seesaw effect is necessary for synergy and to measure the impact of beta-lactam exposure on lipid metabolism. We selected for three isogenic strains with reduced susceptibility to vancomycin, daptomycin, and dalbavancin by serial passaging the MRSA strain N315. We used whole genome sequencing to identify genetic variants that emerged and tested for synergy between vancomycin, daptomycin, or dalbavancin in combination with 6 beta-lactams with variable affinity for staphylococcal penicillin binding proteins (PBPs), including nafcillin, meropenem, ceftriaxone, ceftaroline, cephalexin, and cefoxitin, using time-kills. We observed that the seesaw effect with each beta-lactam was variable and the emergence of the seesaw effect for a particular beta-lactam was not necessary for synergy between that beta-lactam and vancomycin, daptomycin, or dalbavancin. Synergy was more commonly observed with vancomycin and daptomycin based combinations than dalbavancin in time-kills. Among the beta-lactams, cefoxitin and nafcillin were the most likely to exhibit synergy using the concentrations tested, while cephalexin was the least likely to exhibit synergy. Synergy was more common among the resistant mutants than the parent strain. Interestingly N315-D1 and N315-DAL0.5 both had mutations in and despite their differences in the seesaw effect. Lipidomic analysis of all strains exposed to individual beta-lactams at subinhibitory concentrations suggested that in general, the abundance of cardiolipins (CLs) and most free fatty acids (FFAs) positively correlated with the presence of synergistic effects while abundance of phosphatidylglycerols (PGs) and lysylPGs mostly negatively correlated with synergistic effects. In conclusion, the beta-lactam-glycopeptide seesaw effect and beta-lactam-glycopeptide synergy are distinct phenomena. This suggests that the emergence of the seesaw effect may not have clinical importance in terms of predicting synergy. Further work is warranted to characterize strains that don't exhibit beta-lactam synergy to identify which strains should be targeted with combination therapy and which ones cannot and to further investigate the potential role of CLs in mediating synergy.

Keywords

References

  1. Antimicrob Agents Chemother. 2001 Jun;45(6):1799-802 [PMID: 11353628]
  2. Antimicrob Agents Chemother. 2008 Dec;52(12):4289-99 [PMID: 18824611]
  3. Front Microbiol. 2017 Dec 05;8:2303 [PMID: 29259579]
  4. PLoS Genet. 2015 Jul 31;11(7):e1005413 [PMID: 26230489]
  5. Antimicrob Agents Chemother. 2019 Mar 27;63(4): [PMID: 30670436]
  6. Langmuir. 2013 Dec 23;29(51):15878-87 [PMID: 23962277]
  7. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1656-66 [PMID: 26711778]
  8. J Lipid Res. 2017 Apr;58(4):809-819 [PMID: 28167702]
  9. Anal Chem. 2020 Nov 17;92(22):14967-14975 [PMID: 33119270]
  10. J Clin Microbiol. 2015 Apr;53(4):1072-9 [PMID: 25631811]
  11. Fly (Austin). 2012 Apr-Jun;6(2):80-92 [PMID: 22728672]
  12. Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494 [PMID: 29762782]
  13. Antimicrob Agents Chemother. 2013 Jun;57(6):2664-8 [PMID: 23545533]
  14. J Antimicrob Chemother. 2020 May 1;75(5):1182-1186 [PMID: 32016379]
  15. J Bacteriol. 1997 Apr;179(8):2557-66 [PMID: 9098053]
  16. Antimicrob Agents Chemother. 2011 Dec;55(12):5452-8 [PMID: 21947404]
  17. mSphere. 2017 Dec 13;2(6): [PMID: 29242835]
  18. Antimicrob Agents Chemother. 2016 Dec 27;61(1): [PMID: 27795377]
  19. Antimicrob Agents Chemother. 2011 May;55(5):2495-6; author reply 296-7 [PMID: 21527800]
  20. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0035621 [PMID: 34097478]
  21. Trends Microbiol. 2019 Jan;27(1):26-38 [PMID: 30031590]
  22. J Antimicrob Chemother. 2015 Feb;70(2):489-93 [PMID: 25304643]
  23. J Exp Med. 2001 May 7;193(9):1067-76 [PMID: 11342591]
  24. Anal Chem. 2016 Jul 19;88(14):7329-36 [PMID: 27321977]
  25. PLoS One. 2012;7(1):e28316 [PMID: 22238576]
  26. Bioinformatics. 2016 Sep 15;32(18):2847-9 [PMID: 27207943]
  27. Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70 [PMID: 25969447]
  28. Antimicrob Agents Chemother. 2014 Aug;58(8):4593-603 [PMID: 24867990]
  29. J Antimicrob Chemother. 2019 Jan 1;74(1):82-86 [PMID: 30260409]
  30. J Antimicrob Chemother. 2017 May 1;72(5):1410-1414 [PMID: 28158617]
  31. Antimicrob Agents Chemother. 2018 Jun 26;62(7): [PMID: 29735564]
  32. Drug Resist Updat. 2013 Jul-Nov;16(3-5):73-9 [PMID: 24268586]
  33. Antimicrob Agents Chemother. 2013 May;57(5):2376-9 [PMID: 23422917]
  34. Antimicrob Agents Chemother. 2020 Jun 23;64(7): [PMID: 32312776]
  35. Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7077-E7086 [PMID: 27791134]
  36. J Bacteriol. 2012 Mar;194(5):1186-94 [PMID: 22194450]
  37. Antimicrob Agents Chemother. 2012 Dec;56(12):6192-200 [PMID: 22985884]
  38. Microorganisms. 2021 May 11;9(5): [PMID: 34064631]
  39. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66 [PMID: 18725435]
  40. J Am Soc Mass Spectrom. 2017 Mar;28(3):562-565 [PMID: 28074328]
  41. Microbiology (Reading). 2004 Jan;150(Pt 1):45-51 [PMID: 14702396]
  42. Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3722-3727 [PMID: 30808758]
  43. Proc Natl Acad Sci U S A. 2019 Dec 9;: [PMID: 31818937]
  44. Antimicrob Agents Chemother. 2015 Aug;59(8):4930-7 [PMID: 26055370]
  45. mBio. 2017 Oct 31;8(5): [PMID: 29089424]

Grants

  1. R01 AI136979/NIAID NIH HHS
  2. R21 AI132994/NIAID NIH HHS

Word Cloud

Created with Highcharts 10.0.0synergyseesaweffectbeta-lactambeta-lactamsvancomycindaptomycindalbavancinstrainssynergisticbeta-lactam-glycopeptidetestedSynergyexhibitMRSAresistantcommonnecessarystrainidentifycombinationvariablenafcillincephalexincefoxitinusingtime-killsobservedemergencelikelyconcentrationsanalysisabundanceCLscorrelatedeffectsMethicillin-resistantactivityglycopeptides/lipopeptidesManyattributedhoweverassociationrigorouslyobjectivestudydeterminewhethermeasureimpactexposurelipidmetabolismselectedthreeisogenicreducedsusceptibilityserialpassagingN315usedwholegenomesequencinggeneticvariantsemerged6affinitystaphylococcalpenicillinbindingproteinsPBPsincludingmeropenemceftriaxoneceftarolineparticularcommonlybasedcombinationsAmongleastamongmutantsparentInterestinglyN315-D1N315-DAL05mutationsdespitedifferencesLipidomicexposedindividualsubinhibitorysuggestedgeneralcardiolipinsfreefattyacidsFFAspositivelypresencephosphatidylglycerolsPGslysylPGsmostlynegativelyconclusiondistinctphenomenasuggestsmayclinicalimportancetermspredictingworkwarrantedcharacterizetargetedtherapyonesinvestigatepotentialrolemediatingBeta-LactamsLipo-Glyco-LipoglycopeptidesIndependentSeesawEffectMethicillin-Resistantantibacterialslipidomicmembranefluidity

Similar Articles

Cited By (5)